What Is Retatrutide? Triple Agonist Research Guide
Retatrutide is a synthetic triple agonist acting at the GIP, GLP-1 and glucagon receptors. It represents the newest generation of metabolic research compounds and is the natural comparator in study designs that already include Tirzepatide.
Why a third receptor
GIP and GLP-1 agonism operate largely through insulin secretion and appetite signalling. Glucagon receptor agonism adds a distinct axis: energy expenditure and hepatic lipid metabolism.
The research question Retatrutide exists to answer is whether combining an energy-expenditure pathway with the two incretin pathways produces effects beyond dual agonism. That is the core of the current comparative literature.
Structure and handling
Retatrutide is a synthetic peptide based on a GIP analogue backbone with a fatty acid moiety supporting albumin binding and an extended half-life suitable for weekly study intervals.
Handling is identical to other acylated metabolic peptides: reconstitute with bacteriostatic water added down the vial wall, mix by gentle rotation, never shake, and refrigerate the reconstituted vial.
Frequently asked questions
- What receptors does Retatrutide act on?
- Three: the GIP receptor, the GLP-1 receptor and the glucagon receptor. This is what distinguishes it from dual agonists such as Tirzepatide.
- Is Retatrutide approved for human use?
- No. Retatrutide is supplied strictly as a research compound for in-vitro laboratory use and is not a registered medicine in South Africa.
Browse the full Weight Loss & Metabolic Peptides range.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.